To test the hypothesis that cMet inhibition is important for Plk1 inhibitor–induced apoptosis, we treated eight NSCLC cell lines with a combination of volasertib and tepotinib for 72 h and measured viability (Fig 4A). Here, MET is linked to non-small cell lung carcinoma.